-
公开(公告)号：US12077584B2
公开(公告)日：2024-09-03
申请号：US17670398
申请日：2022-02-11
发明人： Natalie Bezman , Alan J. Korman , Shrikant Deshpande , Amy D. Jhatakia , Richard Y. Huang , Guodong Chen , Ginger C. Rakestraw , Karla Ann Henning , Vangipuram S. Rangan , Christine Bee , Xiang Shao
IPC分类号： C07K16/28 , A61K39/00 , A61K39/395 , A61K47/68 , A61P35/00 , C07K1/22 , C12N5/071 , C12N15/85 , C12P21/00 , G01N33/68
CPC分类号： C07K16/2803 , A61K39/3955 , A61K47/6849 , A61P35/00 , C07K1/22 , C12N5/0682 , C12N15/85 , C12P21/005 , G01N33/68 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C12N2510/02 , C12N2800/107
摘要： The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.
-
公开(公告)号：US11274150B2
公开(公告)日：2022-03-15
申请号：US16683927
申请日：2019-11-14
发明人： Natalie Bezman , Alan J. Korman , Shrikant Deshpande , Amy D. Jhatakia , Richard Y. Huang , Guodong Chen , Ginger C. Rakestraw , Karla Ann Henning , Vangipuram S. Rangan , Christine Bee , Xiang Shao
摘要： The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.
-
公开(公告)号：US11981734B2
公开(公告)日：2024-05-14
申请号：US17668807
申请日：2022-02-10
发明人： Natalie Bezman , Alan J. Korman , Shrikant Deshpande , Amy D. Jhatakia , Richard Y. Huang , Guodong Chen , Ginger C. Rakestraw , Karla Ann Henning , Vangipuram S. Rangan , Christine Bee , Xiang Shao
IPC分类号： C07K16/28 , A61K39/395 , A61K47/68 , A61P35/00 , C07K1/22 , C12N5/071 , C12N15/85 , C12P21/00 , G01N33/68 , A61K39/00
CPC分类号： C07K16/2803 , A61K39/3955 , A61K47/6849 , A61P35/00 , C07K1/22 , C12N5/0682 , C12N15/85 , C12P21/005 , G01N33/68 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C12N2510/02 , C12N2800/107
摘要： The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.
-
公开(公告)号：US20220204618A1
公开(公告)日：2022-06-30
申请号：US17670398
申请日：2022-02-11
发明人： Natalie Bezman , Alan J. Korman , Shrikant Deshpande , Amy D. Jhatakia , Richard Y. Huang , Guodong Chen , Ginger C. Rakestraw , Karla Ann Henning , Vangipuram S. Rangan , Christine Bee , Xiang Shao
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
摘要： The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.
-
公开(公告)号：US20170355768A1
公开(公告)日：2017-12-14
申请号：US15531538
申请日：2015-12-03
CPC分类号： C07K16/2818 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/73 , C07K2317/76 , C07K2317/94
摘要： The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-CS1 antibodies in combination with an anti-Programmed Death-1 (PD-1) antibody.
-
公开(公告)号：US20220195042A1
公开(公告)日：2022-06-23
申请号：US17668807
申请日：2022-02-10
发明人： Natalie Bezman , Alan J. Korman , Shrikan Deshpande , Amy D. Jhatakia , Richard Y. Huang , Guodong Chen , Ginger G. Rakestraw , Karla Ann Henning , Vangipuram S. Rangan , Christine Bee , Xiang Shao
摘要： The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.015 秒)
